| 2007 | Outgrowing endothelial cells that are derived from human umbilical cord blood improve neovascularization in hind-limb ischemia. | 성주명; 유은선; 권기환; 이경은; 문영철 | Meeting Abstract |
| 2009 | Reactive Oxygen Species Might Have Important Roles On Angiogenesis of Endothelial Progenitor Cells Derived From HCB(Human Cord Blood) Which Are Stimulated by VEGF. | 성주명; 유은선; 이경은; 문영철; 남은미 | Meeting Abstract |
| 2007 | Restoration of peroxiredoxins and catalase is closely correlated with the level of Philadelphia chromosome during imatinib therapy in CML | 성주명; 이서구; 유은선; 허정원; 이경은; 문영철; 우현애 | Meeting Abstract |
| 2012 | Restrospective Multicenter Study Evaluating Efficacy and Safety of Dasatinib and Nilotinib in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Chronic Phase: Korean CML Working Party | 성주명 | Meeting Abstract |
| 2008 | Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy with Autologous Stem Cell Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial | 성주명 | Meeting Abstract |
| 2006 | The intention to treat analysis of the different post remission therapy modalities in AML patients with the "Intermediate Risk Group (IPG)" based on cytogenetics. | 성주명; 문영철 | Meeting Abstract |
| 2009 | The Level of Peroxiredoxin and Catalase On Single Cell Level Is Correlated with the Positivity of Ph Chromosome in the Bone Marrow of CML Patients During Imatinib Therapy. | 성주명; 이서구; 유은선; 허정원; 이경은; 문영철; 남은미; 우현애 | Meeting Abstract |
| 2006 | The LTB4 receptor is involved not only in the downstream pathway of rhG-CSF mobilization but in the LTB4 mobitization pathway in C57BL/6 mice. | 이순남; 성주명; 유은선; 이경은; 문영철 | Meeting Abstract |
| 2014 | Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer | 이순남; 성순희; 성주명; 이경은; 문영철; 남은미 | Article |
| 2017 | VARIABLE NATURAL KILLER CELL ACTIVITY IN HEMATOLOGIC MALIGNANCIES AT DIAGNOSIS | 성주명; 허정원; 문영철 | Meeting Abstract |
| 2008 | Velcade (R), Thalidomide, Dexamethasone (VTD) Followed by Melphalan, Prednisone, Thalidomide (MPT) Maintenance as a First Line Treatment Demonstrates High Response Rates for High-Risk Patients with Multiple Myeloma (MM) Who Are Non-Transplant Candidates: Updated Results of Phase II Trial. | 성주명 | Meeting Abstract |
| 2007 | Velcade (R), thalidomide, dexamethasone (VTD) induction therapy followed by melphalan, prednisone, thalidomide (MPT) maintenance as a first line treatment for the patients (pts) with multiple myeloma (MM) who are non-transplant candidates: Early analysis from the Korean multiple myeloma working party | 성주명 | Meeting Abstract |
